BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 35144550)

  • 1. Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark.
    Fogh K; Eriksen ARR; Hasselbalch RB; Kristensen ES; Bundgaard H; Nielsen SD; Jørgensen CS; Scharff BFSS; Erikstrup C; Sækmose SG; Holm DK; Aagaard B; Norsk J; Nielsen PB; Kristensen JH; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Simonsen L; Fischer TK; Folke F; Lippert F; Ostrowski SR; Ethelberg S; Koch A; Vangsted AM; Krause TG; Fomsgaard A; Nielsen C; Ullum H; Skov R; Iversen K
    BMC Infect Dis; 2022 Feb; 22(1):143. PubMed ID: 35144550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cross-Sectional Study of SARS-CoV-2 Antibodies and Risk Factors for Seropositivity in Staff in Day Care Facilities and Preschools in Denmark.
    Fogh K; Eriksen ARR; Larsen TG; Hasselbalch RB; Bundgaard H; Scharff BFSS; Nielsen SD; Jørgensen CS; Erikstrup C; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Hindhede L; Mikkelsen S; Sækmose SG; Aagaard B; Holm DK; Harritshøj L; Simonsen L; Fischer TK; Folke F; Lippert F; Ostrowski SR; Benfield T; Mølbak K; Ethelberg S; Koch A; Vangsted AM; Krause TG; Fomsgaard A; Ullum H; Skov R; Iversen K
    Microbiol Spectr; 2023 Feb; 11(1):e0417422. PubMed ID: 36546864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing Denmark: a Danish Nationwide Surveillance Study of COVID-19.
    Fogh K; Strange JE; Scharff BFSS; Eriksen ARR; Hasselbalch RB; Bundgaard H; Nielsen SD; Jørgensen CS; Erikstrup C; Norsk J; Nielsen PB; Kristensen JH; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Simonsen L; Fischer TK; Folke F; Lippert F; Ostrowski SR; Benfield T; Mølbak K; Ethelberg S; Koch A; Sönksen UW; Vangsted AM; Krause TG; Fomsgaard A; Ullum H; Skov R; Iversen K
    Microbiol Spectr; 2021 Dec; 9(3):e0133021. PubMed ID: 34908473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
    Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
    BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study.
    Eriksen ARR; Fogh K; Hasselbalch RB; Bundgaard H; Nielsen SD; Jørgensen CS; Scharff BFSS; Erikstrup C; Sækmose SG; Holm DK; Aagaard B; Kristensen JH; Bødker CA; Norsk JB; Nielsen PB; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Simonsen L; K Fischer T; Folke F; Lippert F; Ostrowski SR; Ethelberg S; Koch A; Vangsted AM; Krause T; Fomsgaard A; Nielsen C; Ullum H; Skov R; Iversen K
    BMC Public Health; 2022 Jun; 22(1):1261. PubMed ID: 35761270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 seroprevalence among 7950 healthcare workers in the Region of Southern Denmark.
    von Huth S; Lillevang ST; Røge BT; Madsen JS; Mogensen CB; Coia JE; Möller S; Justesen US; Johansen IS
    Int J Infect Dis; 2021 Nov; 112():96-102. PubMed ID: 34534698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
    Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC
    Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study.
    Iversen K; Bundgaard H; Hasselbalch RB; Kristensen JH; Nielsen PB; Pries-Heje M; Knudsen AD; Christensen CE; Fogh K; Norsk JB; Andersen O; Fischer TK; Jensen CAJ; Larsen M; Torp-Pedersen C; Rungby J; Ditlev SB; Hageman I; Møgelvang R; Hother CE; Gybel-Brask M; Sørensen E; Harritshøj L; Folke F; Sten C; Benfield T; Nielsen SD; Ullum H
    Lancet Infect Dis; 2020 Dec; 20(12):1401-1408. PubMed ID: 32758438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers.
    Iversen K; Kristensen JH; Hasselbalch RB; Pries-Heje M; Nielsen PB; Knudsen AD; Fogh K; Norsk JB; Andersen O; Fischer TK; Juul Jensen CA; Torp-Pedersen C; Rungby J; Ditlev SB; Hageman I; Møgelvang R; Gybel-Brask M; Dessau RB; Sørensen E; Harritshøj L; Folke F; Sten C; Engel Møller ME; Benfield T; Ullum H; Jørgensen CS; Erikstrup C; Ostrowski SR; Nielsen SD; Bundgaard H
    Clin Microbiol Infect; 2022 May; 28(5):710-717. PubMed ID: 34543759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020.
    Munywoki PK; Nasimiyu C; Alando MD; Otieno N; Ombok C; Njoroge R; Kikwai G; Odhiambo D; Osita MP; Ouma A; Odour C; Juma B; Ochieng CA; Mutisya I; Ngere I; Dawa J; Osoro E; Njenga MK; Bigogo G; Munyua P; Lo TQ; Hunsperger E; Herman-Roloff A
    F1000Res; 2021; 10():853. PubMed ID: 35528961
    [No Abstract]   [Full Text] [Related]  

  • 13. SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.
    Hansen CB; Dvoncova K; Pérez-Alós L; Fogh K; Madsen JR; Garred CH; Jarlhelt I; Nielsen PB; Petersen SS; Fjordager CG; Lauritsen KT; Hilsted L; Boding L; Iversen KK; Hyveled L; Garred P
    J Intern Med; 2023 Jun; 293(6):763-781. PubMed ID: 37024264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.
    Bobrovitz N; Arora RK; Cao C; Boucher E; Liu M; Donnici C; Yanes-Lane M; Whelan M; Perlman-Arrow S; Chen J; Rahim H; Ilincic N; Segal M; Duarte N; Van Wyk J; Yan T; Atmaja A; Rocco S; Joseph A; Penny L; Clifton DA; Williamson T; Yansouni CP; Evans TG; Chevrier J; Papenburg J; Cheng MP
    PLoS One; 2021; 16(6):e0252617. PubMed ID: 34161316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.
    Dimopoulou D; Kyritsi M; Dadouli K; Vergadi E; Tsiligianni E; Papadimitriou E; Mavridi A; Giannakopoulos S; Tsiourvopoulou G; Palyvou M; Angeli E; Brikos N; Eleftheriou I; Spoulou V; Michos A; Gkentzi D; Siomou E; Papaevangelou V; Grivea I; Syrogiannopoulos G; Galanakis E; Hadjichristodoulou C; Tsolia M
    Eur J Pediatr; 2023 Jan; 182(1):439-449. PubMed ID: 36383284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms.
    Javed W; Abidi SHB; Baqar JB
    BMC Infect Dis; 2022 May; 22(1):481. PubMed ID: 35596145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study.
    Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C
    Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.